KPT-330 inhibition of chromosome region maintenance 1 is cytotoxic and sensitizes chronic myeloid leukemia to Imatinib

to related objects

Location
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
2058-7716
Extent
Online-Ressource
Language
Englisch
Notes
online resource.

Bibliographic citation
KPT-330 inhibition of chromosome region maintenance 1 is cytotoxic and sensitizes chronic myeloid leukemia to Imatinib ; volume:4 ; number:1 ; day:23 ; month:4 ; year:2018 ; pages:1-12 ; date:12.2018
Cell death discovery ; 4, Heft 1 (23.4.2018), 1-12, 12.2018

Creator
Nie, Danian
Contributor
Huang, Kezhi
Yin, Songmei
Li, Yiqing
Xie, Shuangfeng
Ma, Liping
Wang, Xiuju
Wu, Yudan
Xiao, Jie
Wang, Jieyu
Yang, Wenjuan
Liu, Hongyun
SpringerLink (Online service)

DOI
10.1038/s41420-018-0049-2
URN
urn:nbn:de:101:1-2018062808321818413285
Rights
Der Zugriff auf das Objekt ist unbeschränkt möglich.
Last update
15.08.2025, 7:35 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Show original at data provider

Associated

  • Nie, Danian
  • Huang, Kezhi
  • Yin, Songmei
  • Li, Yiqing
  • Xie, Shuangfeng
  • Ma, Liping
  • Wang, Xiuju
  • Wu, Yudan
  • Xiao, Jie
  • Wang, Jieyu
  • Yang, Wenjuan
  • Liu, Hongyun
  • SpringerLink (Online service)

Other Objects (12)

Imatinib Mesylate in Chronic Myeloid Leukemia

Imatinib Mesylate in Chronic Myeloid Leukemia

Therapy with Imatinib Mesylate for Chronic Myeloid Leukemia

Therapy with Imatinib Mesylate for Chronic Myeloid Leukemia

Celecoxib suppresses autophagy and enhances cytotoxicity of imatinib in imatinib-resistant chronic myeloid leukemia cells

Celecoxib suppresses autophagy and enhances cytotoxicity of imatinib in imatinib-resistant chronic myeloid leukemia cells

Imatinib Mesylate in Newly Diagnosed Patients of Chronic Myeloid Leukemia

Imatinib Mesylate in Newly Diagnosed Patients of Chronic Myeloid Leukemia

CD45 inhibition in myeloid leukaemia cells sensitizes cellular responsiveness to chemotherapy

CD45 inhibition in myeloid leukaemia cells sensitizes cellular responsiveness to chemotherapy

R132H IDH1 sensitizes glioma to the antiproliferative and cytotoxic effects of BET inhibition

R132H IDH1 sensitizes glioma to the antiproliferative and cytotoxic effects of BET inhibition

First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib

First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib

Improvement of immune thrombocytopenia with imatinib therapy following chronic myeloid leukemia

Improvement of immune thrombocytopenia with imatinib therapy following chronic myeloid leukemia

Specific, targetable interactions with the microenvironment influence imatinib-resistant chronic myeloid leukemia

Specific, targetable interactions with the microenvironment influence imatinib-resistant chronic myeloid leukemia

Discontinuation of imatinib mesylate could improve renal impairment in chronic myeloid leukemia

Discontinuation of imatinib mesylate could improve renal impairment in chronic myeloid leukemia

Down-regulation of miR-181c in imatinib-resistant chronic myeloid leukemia

Down-regulation of miR-181c in imatinib-resistant chronic myeloid leukemia

Specific, targetable interactions with the microenvironment influence imatinib-resistant chronic myeloid leukemia

Specific, targetable interactions with the microenvironment influence imatinib-resistant chronic myeloid leukemia

Related objects